WuXi PharmaTech (Cayman) Inc. reports that its manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd. (STA), has begun operation of a high-potency active pharmaceutical ingredient (HPAPI) laboratory in Shanghai, thereby adding HPAPI processing to its portfolio of services. The laboratory will support process development and clinical-trial supply of high-potency small molecules at kilogram scale.

In May, STA also began construction of a new, fully integrated R&D and cGMP manufacturing site in Changzhou, about 110 miles west of Shanghai.The new campus will be constructed in phases and include both research manufacturing and commercial manufacturing facilities. Facilities constructed in Phase I will double the company’s current manufacturing capacity and be operational by the fourth quarter of 2015. Upon completion of the entire project, the site will triple current capacity and can have more than 1,500 employees, including chemists, production staff, and supporting staff.

Source: Wuxi PharmaTech

 .